Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
Clinical trial NCT06418594 · RECRUITING
Trial details
- NCT number
- NCT06418594
- Sponsor
- Beijing 302 Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-10
- Primary completion
- 2025-11-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.